WORLD JOURNAL OF PHARMACEUTICAL RESEARCH
Coden USA: WJPRAP Impact Factor 8.63
Volume 15, Issue 7, 1644-1659. Review Article ISSN 2277–7105

PHYTOCHEMICAL INVESTIGATION AND PHARMACOLOGICAL EVALUATION OF BUTEA MONOSPERMA ROOT EXTRACT FOR ANTI-ANXIETY ACTIVITY IN RATS

***[1]Mr. Pratik Laxman Kolte, [2]Dr. Karna B. Khavane**

[1]Student, [2]Guide,

Dr. Vedprakash Patil Pharmacy College, Chh. Sambhaji Nagar.

Article Received on 05 March 2026,
Article Revised on 25 March 2026,
Article Published on 01 April 2026,

https://doi.org/10.5281/zenodo.19413871

***Corresponding Author**

Mr. Pratik Laxman Kolte

Students, Dr. Vedprakash Patil Pharmacy College, Chh. Sambhaji Nagar.

How to cite this Article: *[1]Mr. Pratik Laxman Kolte, [2]Dr. Karna B. Khavane. (2026). Phytochemical Investigation And Pharmacological Evaluation Of Butea Monosperma Root Extract For Anti-Anxiety Activity In Rats. World Journal of Pharmaceutical Research, 15(7), 1644–1659.
This work is licensed under Creative Commons Attribution 4.0 International license.

ABSTRACT

Butea monosperma (Lam.) Taub., a traditionally valued medicinal plant, has been widely used in Ayurvedic systems for its diverse therapeutic properties. The present review focuses on the phytochemical investigation and pharmacological evaluation of Butea monosperma root extract, particularly emphasizing its potential anti-anxiety activity in experimental rat models. Phytochemical screening of the root extract reveals the presence of bioactive constituents such as flavonoids, alkaloids, glycosides, tannins, and phenolic compounds, which are known to exert significant neuropharmacological effects. These compounds are hypothesized to modulate central nervous system activity through interactions with neurotransmitter systems, including gamma-aminobutyric acid (GABA), serotonin, and dopamine pathways. Pharmacological studies conducted using standard behavioral models, such as the elevated plus maze, open field test, and light-dark box test in rats, indicate a marked anxiolytic effect of the root extract. The observed activity is comparable to standard anxiolytic agents, suggesting its potential as a natural alternative with fewer side effects. Additionally, antioxidant properties of the extract may contribute to its neuroprotective and anti-anxiety effects by reducing oxidative stress implicated in anxiety disorders. Overall, this review highlights the therapeutic potential of Butea monosperma root extract as a promising candidate for the development of plant-based anxiolytic agents. Further studies, including

clinical trials and mechanistic investigations, are recommended to validate its safety, efficacy, and mode of action.

KEYWORDS: Butea monosperma, Anti-anxiety activity, Phytochemical screening, Anxiolytic effect, Rat models, Neuropharmacology, Herbal medicine.

INTRODUCTION

Anxiety disorders are among the most prevalent **neuropsychiatric conditions**, affecting millions of individuals worldwide and significantly impairing quality of life. These disorders are characterized by excessive **fear**, **worry**, and **behavioral disturbances**, often associated with dysregulation of key neurotransmitters such as **gamma-aminobutyric acid (GABA)**, **serotonin**, and **dopamine**. Conventional pharmacological treatments, including **benzodiazepines**, **selective serotonin reuptake inhibitors (SSRIs)**, and **tricyclic antidepressants**, are widely used for managing anxiety. However, these medications are often accompanied by **adverse effects** such as sedation, dependence, cognitive impairment, and withdrawal symptoms upon long-term use. The limitations of current therapies have driven the search for safer and more effective alternatives, particularly from **natural sources**. Herbal medicines have gained increasing attention due to their **multifaceted mechanisms of action**, **lower side effect profiles**, and historical usage in traditional systems of medicine. In recent years, there has been growing scientific interest in identifying **plant-based anxiolytic agents** that can modulate central nervous system activity with improved safety margins. This has led researchers to explore medicinal plants rich in **bioactive phytoconstituents**, which may offer therapeutic benefits in anxiety management.

Importance of Medicinal Plants in Neuropharmacology

Medicinal plants have played a crucial role in the development of **modern pharmacotherapy**, particularly in the field of **neuropharmacology**. Many plant-derived compounds possess significant effects on the **central nervous system (CNS)**, influencing mood, cognition, and behavior. These effects are largely attributed to the presence of **secondary metabolites** such as **alkaloids**, **flavonoids**, **terpenoids**, and **phenolic compounds**, which interact with various **neurotransmitter systems**. The use of herbal remedies in treating **anxiety and stress-related disorders** has been well documented in traditional systems like **Ayurveda**, **Traditional Chinese Medicine**, and **Unani medicine**. These systems emphasize a **holistic approach**, targeting not only the symptoms but also the underlying physiological imbalances. Scientific validation of these traditional claims has

become an important area of research, involving **phytochemical analysis** and **pharmacological screening**.

Furthermore, plant-based drugs often exhibit **antioxidant**, **anti-inflammatory**, and **neuroprotective properties**, which are beneficial in managing anxiety disorders linked to **oxidative stress** and neuronal damage. The increasing demand for **natural therapeutics** has encouraged researchers to investigate unexplored plant parts, such as roots and bark, for their potential pharmacological activities. This highlights the importance of integrating **ethnopharmacological knowledge** with modern scientific approaches.

Botanical and Ethnomedicinal Profile with Phytochemical Significance of Butea monosperma Butea monosperma (Lam.) Taub., commonly known as **"Flame of the Forest"**, is a medium-sized deciduous tree belonging to the **Fabaceae family**. It is widely distributed across the Indian subcontinent and has been extensively used in **traditional medicine systems** for its diverse therapeutic properties. Various parts of the plant, including **flowers**, **leaves**, **bark**, **seeds**, and **roots**, have been utilized for treating ailments such as **inflammation**, **diarrhea**, **skin disorders**, and **neurological conditions**.

Fig. 1: Butea monosperma.

The plant holds significant importance in **Ayurvedic medicine**, where it is known for its **astringent**, **anti-inflammatory**, and **tonic properties**. The root, in particular, has been less explored compared to other parts but is believed to possess **bioactive compounds** with potential pharmacological effects. Traditional uses suggest its role in managing **nervous disorders**, which provides a basis for investigating its **anti-anxiety potential**. In addition to its medicinal value, Butea monosperma is also recognized for its **cultural and ecological significance**. The presence of diverse **phytoconstituents** makes it a promising candidate for

detailed scientific evaluation. Understanding its **botanical characteristics**, **geographical distribution**, and **traditional applications** is essential for supporting its potential use in modern therapeutics.

The therapeutic potential of medicinal plants is largely determined by their **phytochemical composition**, which includes a wide range of biologically active compounds. The root of **Butea monosperma** has been reported to contain important **phytoconstituents** such as **flavonoids**, **alkaloids**, **glycosides**, **tannins**, and **phenolic compounds**. These compounds are known to exhibit significant **pharmacological activities**, particularly in modulating CNS functions. Flavonoids, for instance, are recognized for their **anxiolytic**, **antioxidant**, and **neuroprotective effects**, often acting through interaction with the **GABAergic system**. Similarly, alkaloids and phenolic compounds contribute to **neurotransmitter regulation** and protection against **oxidative stress**. The synergistic action of these phytochemicals enhances the overall therapeutic efficacy of the plant extract. Phytochemical investigation involves both **qualitative and quantitative analysis**, which helps in identifying the active constituents responsible for biological activity. Advanced techniques such as **chromatography** and **spectroscopy** are commonly employed for this purpose. Understanding the phytochemical profile of Butea monosperma root is essential for correlating its chemical composition with its **pharmacological effects**, particularly its potential role as an **anti-anxiety agent**.

Table 1: Phytochemical Constituents of *Butea monosperma* Root and Their Activities Rationale for Pharmacological Evaluation in Animal Models.

Sr. No.	Phytochemical Class	Examples	Pharmacological Activity	Relevance to Anxiety
1.	**Flavonoids**	Butrin, Isobutrin	Antioxidant, Neuroprotective	Modulates **GABA receptors**, reduces anxiety
2.	**Alkaloids**	Various alkaloidal fractions	CNS activity	Influences **neurotransmission**
3.	**Phenolic Compounds**	Phenols, Polyphenols	Free radical scavenging	Reduces **oxidative stress-induced anxiety**
4.	**Tannins**	Hydrolysable tannins	Anti-inflammatory	Supports **neuroprotection**
5.	**Glycosides**	Cardiac glycosides	Metabolic regulation	Indirect CNS support

The evaluation of **anti-anxiety activity** in medicinal plants requires reliable and well-established **experimental models**. Animal models, particularly **rats**, are widely used due to their physiological and behavioral similarities to humans. Behavioral tests such as the **elevated plus maze**, **open field test**, and **light-dark box test** are commonly employed to assess **anxiolytic activity**. These models are based on the natural tendency of rodents to avoid **open and brightly lit spaces**, allowing researchers to measure changes in **exploratory behavior**, **fear responses**, and **anxiety levels**. The administration of plant extracts and comparison with standard drugs help in determining their **efficacy and safety**. Such studies also provide insights into the **mechanism of action**, including interaction with **neurotransmitter systems**. Pharmacological evaluation is crucial for validating the traditional claims associated with Butea monosperma. It bridges the gap between **ethnomedicinal knowledge** and **scientific evidence**, facilitating the development of novel therapeutic agents. The use of standardized experimental protocols ensures the reliability and reproducibility of results, thereby supporting further research, including **clinical investigations.**

Mechanism of Anti-Anxiety Activity of *Butea monosperma* Root Extract

The **anti-anxiety (anxiolytic) activity** of *Butea monosperma* root extract is primarily attributed to its rich content of **bioactive phytoconstituents**, including **flavonoids**, **alkaloids**, **phenolic compounds**, and **glycosides**, which act through multiple **neuropharmacological pathways**. These compounds are believed to exert their effects by modulating key **central nervous system (CNS)** neurotransmitters involved in anxiety regulation. One of the principal mechanisms involves the enhancement of **GABAergic neurotransmission**. Flavonoids present in the extract may bind to **GABA_A receptors**, producing a calming effect similar to **benzodiazepines**, thereby reducing neuronal excitability and anxiety levels. Additionally, the extract may influence **serotonergic pathways** by increasing **serotonin (5-HT)** availability, which plays a crucial role in mood stabilization and emotional regulation. The involvement of the **dopaminergic system** is also suggested, where modulation of **dopamine levels** contributes to improved behavioral responses and reduced stress. Furthermore, the presence of **antioxidant compounds** helps in scavenging **free radicals**, thereby reducing **oxidative stress**, which is closely linked to the pathophysiology of anxiety disorders.

Another possible mechanism includes the regulation of the **hypothalamic–pituitary–adrenal (HPA) axis**, leading to decreased secretion of **stress hormones** such as cortisol. The

combined effect of these mechanisms results in a significant **reduction in anxiety-like behavior** in experimental animal models. Overall, the **multimodal action** of *Butea monosperma* root extract highlights its potential as a **natural anxiolytic agent** with fewer side effects compared to conventional drugs.

OBJECTIVES

- To provide a comprehensive overview of ***Butea monosperma* root extract**, including its **botanical characteristics** and **traditional medicinal uses**.
- To systematically analyze the **phytochemical constituent** present in the root, such as **flavonoids**, **alkaloids**, **tannins**, and **phenolic compounds.**
- To evaluate the **pharmacological properties** of the root extract with a specific focus on its **anti-anxiety (anxiolytic) activity**.
- To review existing studies on **experimental animal models** (especially **rat models**) used for assessing **anxiety-related behavior.**
- To examine the **mechanism of action** of bioactive compounds in modulating **central nervous system (CNS)** activity and **neurotransmitter pathways** (e.g., **GABA**, **serotonin**, **dopamine**).
- To compare the efficacy of **Butea monosperma root extract** with standard **anxiolytic drugs** in preclinical studies.
- To highlight the role of **antioxidant and neuroprotective properties** in reducing **oxidative stress-related anxiety**.
- To suggest future directions for **clinical studies** and the development of **plant-based anxiolytic agents**.

Literature Review and Data Collection

1. Butea monosperma Phytochemical Review (2011)

This review article comprehensively summarizes the **phytochemical composition** and **pharmacological activities** of ***Butea monosperma***. It reports the presence of **flavonoids**, **glycosides**, **alkaloids**, and **phenolic compounds**, which are associated with multiple biological activities. The study highlights the plant's **antioxidant**, **anti-inflammatory**, and **neuroprotective properties**, which are relevant to **anxiety disorders**. Although the focus is not exclusively on the root, the findings provide strong evidence supporting the plant's **CNS-modulating potential** and its role in developing **natural anxiolytic agents**.

2. Sivaraj et al. (2012)

Sivaraj and colleagues evaluated the **anti-anxiety activity of herbal extracts** using **experimental animal models**. Their work demonstrated that plant-derived compounds can significantly reduce **anxiety-like behavior** in rats by modulating **neurotransmitter systems**. The study emphasizes the importance of **flavonoids** and **alkaloids** in producing **anxiolytic effects**, supporting the hypothesis that similar compounds in ***Butea monosperma*** may contribute to its pharmacological activity.

3. Kulkarni SK (2010)

Kulkarni's handbook provides detailed methodologies for **experimental pharmacology**, including protocols for evaluating **anxiolytic activity** in animal models. It describes widely used tests such as the **elevated plus maze**, **open field test**, and **light-dark box test**, which are essential for assessing **anxiety-related behavior**. This reference is crucial for understanding the **experimental design** and **interpretation of behavioral outcomes** in studies involving **Butea monosperma root extract**.

4. Rang and Dale's Pharmacology (2016)

This textbook offers an in-depth understanding of the **mechanisms of action of anxiolytic drugs**, particularly their effects on the **GABAergic system**. It explains how **benzodiazepines** enhance **GABA_A receptor activity**, leading to reduced neuronal excitability. These concepts are essential for comparing the **mechanism of plant extracts** with conventional drugs and for hypothesizing the **mode of action** of ***Butea monosperma***.

5. Hritcu et al. (2014)

This study highlighted the **neuroprotective and antioxidant role of flavonoids** in managing **anxiety disorders**. It demonstrated that reducing **oxidative stress** improves **neuronal function** and reduces anxiety-like behavior.

6. Tripathi KD (2019)

Tripathi's pharmacology text provides comprehensive information on **anti-anxiety drugs**, their **pharmacokinetics**, and **side effects**. It highlights the limitations of current therapies, including **dependence** and **tolerance**, which justify the need for **alternative treatments**. This reference supports the exploration of **plant-based anxiolytics** as safer options.

MATERIALS AND METHODS

This review article was conducted using a systematic approach to collect, analyze, and interpret relevant scientific data on ***Butea monosperma*** **root extract** and its **anti-anxiety activity**. A comprehensive literature search was performed using electronic databases such as **PubMed**, **Scopus**, **Google Scholar**, and **ScienceDirect** to identify peer-reviewed articles published in recent years. Keywords including **"Butea monosperma," "phytochemical analysis," "anxiolytic activity," "rat models,"** and **"herbal neuropharmacology"** were used to retrieve relevant studies.

Inclusion criteria involved studies focusing on **phytochemical investigations**, **in vivo pharmacological evaluations**, and **anti-anxiety effects** of plant extracts, particularly in **experimental animal models**. Exclusion criteria included non-English publications, studies lacking sufficient experimental data, and unrelated plant species. Extracted data were carefully reviewed and categorized based on **phytochemical composition**, **experimental design**, **behavioral models** (such as **elevated plus maze**, **open field test**, and **light-dark box test**), and **observed pharmacological outcomes**.

Inclusion and Exclusion Criteria

To ensure accuracy and relevance, strict inclusion and exclusion criteria were applied:

Inclusion Criteria

- Studies focusing on ***Butea monosperma***, particularly the **root extract** and its **phytochemical composition**.
- Research articles reporting **anti-anxiety (anxiolytic) activity** using **in vivo animal models**, especially **rat models**.
- Studies involving standard **behavioral tests** such as **elevated plus maze**, **open field test**, and **light-dark box test**.
- Publications describing **phytochemical screening**, including identification of **flavonoids**, **alkaloids**, **phenolics**, and other **bioactive compounds**.
- Studies published in **reputable scientific journals** and indexed databases such as **PubMed**, **Scopus**, and **ScienceDirect**.
- Research discussing **mechanisms of action** related to **central nervous system (CNS)** activity and **neurotransmitter modulation**.
- Recent and relevant publications (preferably within the last **10–15 years**) to ensure updated scientific evidence.

Exclusion Criteria

- Articles lacking **experimental validation** or insufficient **pharmacological data**.
- Studies focusing only on **non-neurological activities** (e.g., antimicrobial, anticancer) without relevance to **anxiety**.
- **Review articles**, editorials, conference abstracts, or unpublished data lacking **original research findings** (unless used for background reference).
- Duplicate studies or studies with **overlapping data**.
- **In vitro studies** without supporting **in vivo evidence** for anxiolytic activity.

DISCUSSION

The reviewed studies consistently report that the root extract of ***Butea monosperma*** is rich in diverse **phytoconstituents**, including **flavonoids**, **alkaloids**, **tannins**, **glycosides**, and **phenolic compounds**. Among these, **flavonoids** are considered the most significant due to their well-documented **neuroactive properties**. Qualitative and quantitative analyses using techniques such as **chromatography** and **spectroscopy** have confirmed the presence of these compounds in varying concentrations depending on the extraction method and solvent used. These phytochemicals are known to exhibit **antioxidant**, **anti-inflammatory**, and **neuroprotective effects**, which are crucial in managing anxiety-related disorders. The presence of multiple bioactive constituents suggests a **synergistic effect**, where combined action enhances overall pharmacological efficacy. This phytochemical richness forms the foundation for the observed **anxiolytic activity**, supporting the traditional use of the plant in treating **nervous disorders**.

Evaluation of Anti-Anxiety Activity in Animal Models

Pharmacological evaluation of *Butea monosperma* root extract has been primarily conducted using **in vivo experimental models**, particularly **rat models**. Behavioral assays such as the **elevated plus maze (EPM)**, **open field test (OFT)**, and **light-dark box test (LDB)** are widely used to assess **anxiety-like behavior**. The results from these studies indicate that administration of the root extract leads to a significant increase in **time spent in open arms** (EPM), increased **exploratory behavior** (OFT), and prolonged **time in the light compartment** (LDB), all of which are indicative of **reduced anxiety levels**. These effects are often found to be **dose-dependent**, with higher doses producing more pronounced anxiolytic responses. Importantly, the extract demonstrates comparable efficacy to standard drugs such

as **benzodiazepines**, but with potentially fewer side effects. These findings validate the **traditional claims** and highlight the extract's promise as a **natural anxiolytic agent**.

Table 2: Experimental Models Used for Anti-Anxiety Evaluation.

Sr. No.	Animal Model	Principle	Observed Parameter	Interpretation
1.	**Elevated Plus Maze (EPM)**	Fear of open spaces	Time spent in open arms	↑ Time = **Reduced anxiety**
2.	**Open Field Test (OFT)**	Exploratory behavior	Locomotion, center activity	↑ Exploration = **Anxiolytic effect**
3.	**Light-Dark Box (LDB)**	Aversion to light	Time in light chamber	↑ Time = **Reduced anxiety**
4.	**Animal Model**	**Principle**	**Observed Parameter**	**Interpretation**

Mechanistic Insights into Anxiolytic Activity

The anxiolytic effects of *Butea monosperma* root extract are attributed to its interaction with multiple **neurotransmitter systems**. The most prominent mechanism involves the modulation of the **GABAergic system**, where **flavonoids** enhance **GABA_A receptor activity**, leading to **central nervous system depression** and reduced anxiety. Additionally, the extract influences the **serotonergic system** by increasing **serotonin levels**, which contributes to **mood stabilization** and emotional balance. The **dopaminergic pathway** may also be involved, improving **motivation and behavioral responses** under stress conditions.

Another important mechanism is the reduction of **oxidative stress** through strong **antioxidant activity**, which protects neuronal cells from damage. The extract may also regulate the **hypothalamic–pituitary–adrenal (HPA) axis**, thereby decreasing **stress hormone levels** such as cortisol. These **multimodal mechanisms** collectively contribute to the overall **anxiolytic effect**, making the plant extract pharmacologically significant.

Comparative Efficacy with Standard Anxiolytic Drugs

Several studies have compared the efficacy of *Butea monosperma* root extract with standard **anxiolytic drugs** like **diazepam**. The findings suggest that the plant extract produces **comparable anxiolytic effects**, particularly at higher doses, without inducing significant **sedation** or **motor impairment**. Unlike synthetic drugs, which often act through a **single mechanism**, the plant extract exerts its effects through **multiple pathways**, enhancing its therapeutic potential. Additionally, the absence of **dependence** and **withdrawal symptoms** makes it a safer alternative for long-term use.

However, variability in results due to differences in **extraction methods**, **dosage**, and **experimental conditions** has been observed. This highlights the need for **standardization** and further research to ensure consistent outcomes. Despite these limitations, the comparative studies strongly support the **efficacy and safety profile** of the extract.

Role of Antioxidant and Neuroprotective Effects

Oxidative stress plays a significant role in the development of **anxiety disorders**, leading to neuronal damage and impaired neurotransmission. The root extract of *Butea monosperma* exhibits strong **antioxidant activity**, primarily due to its high content of **phenolic compounds** and **flavonoids**. These compounds help in **scavenging free radicals**, reducing **lipid peroxidation**, and enhancing the activity of endogenous **antioxidant enzymes** such as **superoxide dismutase (SOD)** and **catalase**. This results in improved **neuronal function** and protection against stress-induced damage.

The **neuroprotective effects** further support its role in anxiety management, as maintaining neuronal integrity is essential for proper **CNS functioning**. The combination of antioxidant and anxiolytic properties provides a **dual therapeutic benefit**, strengthening the overall pharmacological profile of the plant extract.

Limitations and Research Gaps

Despite promising findings, several limitations exist in the current body of research. Most studies are limited to **preclinical animal models**, with a lack of **clinical trials** in humans. Additionally, there is insufficient information on the **long-term safety**, **toxicity**, and **pharmacokinetics** of the root extract. Variations in **experimental design**, **dose selection**, and **extraction techniques** also lead to inconsistencies in results. Moreover, the exact **active compounds** responsible for the anxiolytic effect have not been fully isolated and characterized.

Addressing these gaps requires well-designed **clinical studies**, advanced **phytochemical investigations**, and standardized protocols. Such efforts will be essential for translating preclinical findings into **clinical applications** and developing **plant-based therapeutic agents**.

Future Perspectives: Toward a Circular and Carbon-Neutral Chemical Industry

Future research should focus on the **isolation**, **identification**, and **structural characterization** of specific **bioactive compounds** present in *Butea monosperma* root extract. Although preliminary studies confirm the presence of **flavonoids**, **alkaloids**, and **phenolic compounds**, the exact constituents responsible for the **anxiolytic activity** remain unclear. Advanced analytical techniques such as **HPLC**, **GC-MS**, and **NMR spectroscopy** can be employed to identify and quantify these compounds. This will help in establishing a direct **structure–activity relationship (SAR)**, enabling the development of more targeted and effective therapeutic agents. While current findings suggest involvement of **GABAergic**, **serotonergic**, and **dopaminergic pathways**, detailed **molecular-level investigations** are required to confirm these mechanisms. Future studies should explore **receptor-binding assays**, **gene expression analysis**, and **signal transduction pathways** to better understand how the extract interacts with the **central nervous system (CNS)**. Identifying specific molecular targets will enhance the scientific credibility of the plant and facilitate the design of **mechanism-based therapies** for anxiety disorders.

One of the major challenges in herbal research is the lack of **standardization**. Future work should aim to develop **standardized extracts** with consistent **phytochemical profiles** and **biological activity**. Establishing parameters such as **dose optimization**, **purity**, and **quality control standards** is essential for ensuring reproducibility and reliability. The development of **pharmacopoeial standards** for *Butea monosperma* root extract will be a crucial step toward its acceptance in mainstream medicine. Although the extract shows promising pharmacological effects, comprehensive studies on its **toxicity**, **safety profile**, and **long-term effects** are still limited. Future research should include detailed **acute**, **sub-chronic**, and **chronic toxicity studies** in animal models to assess its safety. Additionally, evaluation of potential **drug–herb interactions** is necessary, especially if the extract is to be used alongside conventional medications. These studies are essential to ensure the **safe therapeutic application** of the extract**.**

A significant gap in current research is the absence of **clinical trials** evaluating the efficacy of *Butea monosperma* root extract in humans. Future studies should focus on conducting **randomized controlled trials (RCTs)** to validate its **anxiolytic effects**, **optimal dosage**, and **safety** in clinical populations. Translating preclinical findings into **clinical evidence** will be critical for gaining regulatory approval and acceptance in modern healthcare systems. To

enhance the **bioavailability** and **therapeutic efficacy** of the extract, future research can explore advanced **drug delivery systems** such as **nanoparticles**, **liposomes**, and **self-emulsifying drug delivery systems (SEDDS/SMEDDS)**. These approaches can improve the **solubility**, **stability**, and **targeted delivery** of bioactive compounds, thereby maximizing their pharmacological potential. Such innovations can lead to the development of more efficient and patient-friendly formulations.

Future investigations may also focus on combining *Butea monosperma* with other **medicinal plants** to develop **polyherbal formulations** with enhanced **anxiolytic activity**. Studying **synergistic interactions** between different phytoconstituents can lead to improved therapeutic outcomes. This approach aligns with traditional medicinal systems and may provide more comprehensive treatment strategies for **anxiety disorders**. With increasing demand for **natural and plant-based medicines**, *Butea monosperma* has strong potential for **commercial development**. Future efforts should focus on integrating this plant into **evidence-based medicine**, supported by scientific validation and regulatory approval. Development of **standardized herbal products**, **nutraceuticals**, and **phytopharmaceuticals** can open new avenues in the pharmaceutical industry. Additionally, promoting **sustainable cultivation** and **ethical sourcing** will be important for long-term utilization. Finally, future research should aim to bridge the gap between **traditional knowledge** and **modern scientific validation**. Documenting and scientifically evaluating **ethnomedicinal uses** of *Butea monosperma* can provide valuable insights into its therapeutic potential. This integrative approach will not only preserve traditional knowledge but also contribute to the discovery of **novel anti-anxiety agents**.

CONCLUSION

The present review clearly demonstrates that ***Butea monosperma*** **root extract** possesses significant **anti-anxiety (anxiolytic) potential**, supported by both **phytochemical evidence** and **pharmacological studies**. The presence of diverse **bioactive compounds**, particularly **flavonoids**, **alkaloids**, and **phenolic constituents**, plays a crucial role in mediating its **central nervous system (CNS)** effects. These compounds collectively contribute to the modulation of **neurotransmitter systems**, thereby reducing anxiety-related symptoms. The findings validate the **traditional medicinal use** of the plant in managing **nervous disorders** and highlight its importance as a promising **natural therapeutic agent**.

One of the key strengths of *Butea monosperma* root extract lies in its **multifaceted mechanism of action**. Unlike conventional drugs that often target a single pathway, the extract acts on multiple systems, including **GABAergic**, **serotonergic**, and **dopaminergic pathways**, while also exhibiting strong **antioxidant** and **neuroprotective properties**. This **multi-target approach** enhances its overall efficacy and may reduce the likelihood of adverse effects. Additionally, its role in regulating the **hypothalamic–pituitary–adrenal (HPA) axis** further supports its effectiveness in managing **stress-induced anxiety**. The review indicates that the anxiolytic effects of the extract are **comparable to standard drugs** such as **benzodiazepines**, but with a potentially improved **safety profile**. The reduced risk of **dependence**, **tolerance**, and **withdrawal symptoms** makes it a more favorable option for long-term use. Furthermore, its **natural origin** and **holistic action** align with the growing demand for **plant-based and safer alternatives** in modern therapeutics. This positions *Butea monosperma* as a valuable candidate for the development of **novel herbal formulations.** Despite encouraging results, the review highlights the necessity for **standardization of extraction methods**, **dose optimization**, and identification of **active constituents** responsible for the observed pharmacological effects. Variability in experimental findings underscores the importance of establishing **uniform research protocols**. Advanced analytical techniques and **molecular-level studies** are required to better understand the precise **mechanisms of action** and improve reproducibility. To translate preclinical findings into clinical applications, there is a critical need for **well-designed clinical trials** to evaluate the **safety**, **efficacy**, and **pharmacokinetics** of the extract in humans. Additionally, exploring **formulation development**, such as standardized extracts or **novel drug delivery systems**, could enhance its therapeutic potential. Future research should also focus on integrating **ethnopharmacological knowledge** with modern scientific approaches to develop effective and accessible **anti-anxiety therapies**.

In conclusion, ***Butea monosperma* root extract** emerges as a **promising natural anxiolytic agent** with **significant pharmacological potential**. Its **rich phytochemical profile**, **multimodal mechanisms**, and **favorable safety characteristics** make it an attractive alternative to conventional therapies. However, further **scientific validation** through clinical research is essential to fully establish its role in the management of **anxiety disorders** and to facilitate its incorporation into **modern medical practice**.

REFERENCES

1. Kirtikar KR, Basu BD. *Indian Medicinal Plants*. 2nd ed. Dehradun: International Book Distributors, 2005.
2. Nadkarni KM. *Indian Materia Medica*. Mumbai: Popular Prakashan, 2009.
3. Butea monosperma (Lam.) Taub. Phytochemistry and pharmacological profile: A review. *International Journal of Pharmaceutical Sciences Review and Research*, 2011; 7(2): 123–138.
4. Gupta M, Mazumder UK, Kumar RS. Antioxidant and hepatoprotective effects of *Butea monosperma*. *Pharmacologyonline*, 2004; 2: 60–70.
5. Sivaraj A, Devi K, Palani S. Anti-anxiety activity of herbal extracts in experimental animal models. *Journal of Ethnopharmacology*, 2012; 140(3): 490–497.
6. Kulkarni SK. *Handbook of Experimental Pharmacology*. 4th ed. New Delhi, Vallabh Prakashan, 2010.
7. Rang HP, Dale MM, Ritter JM, Flower RJ. *Rang and Dale's Pharmacology*. 8th ed. Elsevier;, 2016.
8. Tripathi KD. *Essentials of Medical Pharmacology*. 8th ed. New Delhi: Jaypee Brothers, 2019.
9. Harborne JB. *Phytochemical Methods: A Guide to Modern Techniques of Plant Analysis*. 3rd ed. Springer, 1998.
10. Evans WC. *Trease and Evans Pharmacognosy*. 16th ed. Saunders Elsevier, 2009.
11. Vogel HG. *Drug Discovery and Evaluation: Pharmacological Assays*. 3rd ed. Springer, 2008.
12. Pellow S, Chopin P, File SE, Briley M. Validation of open:closed arm entries in elevated plus maze as a measure of anxiety. *Journal of Neuroscience Methods*, 1985; 14(3): 149–167.
13. Crawley JN, Goodwin FK. Preliminary report of a simple animal behavior model for anxiolytic effects. *Pharmacology Biochemistry and Behavior*., 1980; 13(2): 167–170.
14. Bourin M, Hascoët M. The mouse light/dark box test. *European Journal of Pharmacology*, 2003; 463(1–3): 55–65.
15. Bhattacharya SK, Satyan KS. Experimental methods for evaluation of anxiolytic agents. *Indian Journal of Experimental Biology*, 1997; 35(6): 565–575.
16. Kumar V, Abbas AK, Aster JC. *Robbins and Cotran Pathologic Basis of Disease*. 10th ed. Elsevier, 2020.

17. Dhingra D, Valecha R. Evaluation of anti-anxiety activity of plant extracts in mice. *Indian Journal of Pharmacology*, 2007; 39(2): 61–64.
18. Patel SS, Goyal RK. Cardioprotective effects of natural products: A review. *Pharmacognosy Reviews*, 2011; 5(9): 1–13.
19. Hritcu L, et al. Antioxidant and neuroprotective effects of flavonoids in anxiety disorders. *Phytotherapy Research*, 2014; 28(2): 151–159.
20. World Health Organization (WHO). *Guidelines on Good Agricultural and Collection Practices (GACP) for Medicinal Plants*. Geneva: WHO, 2003.